Biotech & AI drug discoveryNature Medicine

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Two randomized, controlled phase 3 STOP-V trials investigated povorcitinib as a treatment for nonsegmental vitiligo, reported by Nature Medicine. The supplied context contains no specific trial results, so no outcomes can be stated.

AI summary · generated only from source feed metadata; consult original

Source published2026-11-02T00:00:00+00:00

Published here2026-11-03T02:25:38+00:00

Original source

Nature Medicine

Media report · consult original reporting

Read the original ↗https://www.nature.com/articles/s41591-026-04739-2

Original headline

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.